相似文献
1
Fluke-Related Cholangiocarcinoma: Challenges and Opportunities.
Pathogens. 2023 Dec 8;12(12):1429. doi: 10.3390/pathogens12121429.
2
Liver Fluke-Associated Biliary Tract Cancer.
Gut Liver. 2018 May 15;12(3):236-245. doi: 10.5009/gnl17102.
3
Expected rate of liver fluke-related cholangiocarcinoma in endemic area of liver fluke with antiparasitic drug distribution program for disease control in Thailand.
J Cancer Res Ther. 2022 Jul-Sep;18(4):927-930. doi: 10.4103/jcrt.JCRT_783_19.
4
Biliary tract malignancies: a population-based study on incidence, prognosis and management of patients.
Scand J Gastroenterol. 2016 Dec;51(12):1520-1525. doi: 10.1080/00365521.2016.1218538. Epub 2016 Aug 24.
5
Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes.
J Clin Pathol. 2006 Oct;59(10):1073-8. doi: 10.1136/jcp.2005.033712. Epub 2006 May 5.
6
Liver fluke granulin promotes extracellular vesicle-mediated crosstalk and cellular microenvironment conducive to cholangiocarcinoma.
Neoplasia. 2020 May;22(5):203-216. doi: 10.1016/j.neo.2020.02.004. Epub 2020 Mar 31.
7
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
Medicina (Kaunas). 2021 Nov 27;57(12):1301. doi: 10.3390/medicina57121301.
8
Associations of Liver Fluke Infection and Cholangiocarcinoma: A Scoping Review.
Cureus. 2023 Oct 3;15(10):e46400. doi: 10.7759/cureus.46400. eCollection 2023 Oct.
9
Worldwide trends in mortality from biliary tract malignancies.
BMC Cancer. 2002 May 3;2:10. doi: 10.1186/1471-2407-2-10.
10
Epigenome Remodeling in Cholangiocarcinoma.
Trends Cancer. 2019 Jun;5(6):335-350. doi: 10.1016/j.trecan.2019.05.002. Epub 2019 Jun 4.
本文引用的文献
1
Targeted Therapies in Advanced Cholangiocarcinoma.
Life (Basel). 2023 Oct 16;13(10):2066. doi: 10.3390/life13102066.
2
-Current Understanding of the Neglected Hepatobiliary Parasite.
Pathogens. 2023 Jun 2;12(6):795. doi: 10.3390/pathogens12060795.
3
Immunology and immunotherapy of cholangiocarcinoma.
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):349-365. doi: 10.1038/s41575-022-00741-4. Epub 2023 Jan 25.
4
Efficacy of drugs against clonorchiasis and opisthorchiasis: a systematic review and network meta-analysis.
Lancet Microbe. 2022 Aug;3(8):e616-e624. doi: 10.1016/S2666-5247(22)00026-X. Epub 2022 Jun 10.
5
Reduction of Reinfection Rates with Opisthorchis viverrini through a Three-Year Management Program in Endemic Areas of Northeastern Thailand.
Korean J Parasitol. 2020 Oct;58(5):527-535. doi: 10.3347/kjp.2020.58.5.527. Epub 2020 Oct 22.
6
IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting.
Cancers (Basel). 2020 Nov 9;12(11):3310. doi: 10.3390/cancers12113310.
7
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
8
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
9
Human liver flukes.
Lancet Gastroenterol Hepatol. 2017 Sep;2(9):680-689. doi: 10.1016/S2468-1253(17)30111-5.
10
Reversal of biliary tract abnormalities associated with Opisthorchis viverrini infection following praziquantel treatment.
Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):194-7. doi: 10.1016/0035-9203(93)90489-d.
Zotero 插件